TMU BioMed Accelerator
VC Fund
Taipei, Taiwan
TMU BioMed Accelerator is a VC fund in Taipei focused on Health Care and Medical Device. TMU BioMed Accelerator operates as a medical university accelerator with a perfect medical market place, clinical advantages, biomedical and artificial intelligence talents.
- Total investments:
- 55
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries TMU BioMed Accelerator invests in
Health CareMedical DeviceArtificial IntelligenceMedicalSoftware
Stages TMU BioMed Accelerator invests in
SeedPre-SeedSeries AVenture - Series UnknownSeries B
Countries TMU BioMed Accelerator invests in
TaiwanSingaporeUnited StatesCanadaChina
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jowy Tani
|
|||
Investment Focus
Industry
- Health Care 32 (58%)
- Medical Device 18 (33%)
- Artificial Intelligence 18 (33%)
- Medical 17 (31%)
- Software 16 (29%)
Stage
- Seed 46 (84%)
- Pre-Seed 3 (5%)
- Series A 2 (4%)
- Venture - Series Unknown 2 (4%)
- Series B 1 (2%)
Country
- Taiwan 28 (51%)
- Singapore 6 (11%)
- United States 6 (11%)
- Canada 3 (5%)
- China 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jowy Tani
CEO
|
CEO | Total investments: 7 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
MedicalTek
|
MedicalTek Co., Ltd. (MDTK) strives to excellence in ingenuity and quality and is committed to continue delivering reliable and user friendly solutions to the health and medical industries. The company keep on focusing on the unmet needs that exist in the Minimally Invasive Surgery, to develop and manufacture the products that can be closer to theneeds of surgeons. | $3.7M / Series A / Dec 30, 2024 | |
NousQ Pte Ltd
|
NousQ is the inventor of CLiKX, the world’s first handheld robotic device with sensors to treat glue ears. Otitis Media with Effusion (or “glue ears”) is the foremost reason why children visit a doctor. It affects the hearing of millions of children worldwide annually. When conservative treatments do not work, surgery is required to place a tinyventilation tube to drain the fluid from the middle ear. Given the invasive nature of the current surgery, an operating theatre, general anaesthesia and a large non-portable surgical microscope is needed. With CLiKX, we are able to move the surgery out of the operating theatre into the clinic using local anaesthesia and without the large surgical microscope. This drastically reduces treatment time, procedure costs and the long waiting time for surgery. | $2.1M / Seed / Mar 18, 2024 | |
Pythia Biotech
|
Pythia Biotech provides organ-on-chip and drug screening. It aims to reduce the burden of a therapeutic try when cancer treatment fails. Organ-on-chip will be an alternative or avatar for cancer patients. It was founded in 2022 and is located in Taipei, Taiwan. | Seed / Feb 26, 2024 | |
Auspex Diagnostics
|
AI startup that provides treatment personalization using patients' tumor samples | Seed / Feb 26, 2024 | |
BROADSIMS Inc.
|
Telehealth, RPM, MIoT, RPM, 5G, App | Seed / Feb 26, 2024 | |
AeproMED
|
AeproMED's advanced inhalation therapy platform offers quick therapeutic onset while minimizing systemic side effects. Leveraging professional aerosol science, it ensures precise drug-aerosol delivery directly to the lungs. This versatile technology supports animal pre-clinical trials, supportive therapies, and lung disease treatment. Designedwith a user-centric approach, it integrates seamlessly with respiratory medicine for chronic disease management. Additionally, it provides cutting-edge technology for developing new compounds to treat cancer or for supportive therapies in sub-health conditions. AeproMED's platform is a significant advancement in the medical and healthcare fields. | Seed / Feb 26, 2024 | |
INVENIS BIOTHERAPIES
|
InVenis Biotherapies is a biotech compagny developping innovative regenerative therapies based on blood platelet. | Seed / Feb 26, 2024 | |
Instant NanoBiosensors
|
Instant NanoBiosensors Co., Ltd. was founded in August 2016, with operation sites in Taipei and the USA. As of now, we have more than a dozen employees, including experts in biology, microfluidics, chemistry, machinery, integration of software and hardware, AI algorithm, marketing, and business development. In May 2019, we launched Light SensingBiomarker Analyzer, which won its first overseas order from Brigham and Women's Hospital (BWH), a teaching hospital of Harvard Medical School. We also have been working with BWH in clinical studies. In 2020, Instant NanoBiosensors was one the 12 innovative young companies for worldwide strategic collaboration selected by Merck KGaA. We were selected out of 500 candidates from around the world because of our unique fiber optic microfluidics nano-chip technology. As we can analyze -- with three easy steps -- proteins and nucleic acids like top laboratories, we were the only Asian company selected by Merck KGaA.Researchers and clinicians rely extensively on biomarkers as research and clinical tools. However, many biomarkers are not detectable using conventional technologies. Under this circumstance, biomarkers only detected with relatively narrow ranges that reflect more advanced disease conditions. For advanced medical research and early disease diagnosis, the biomarker detection range need to expand into wide range. Our platform utilizes patented Fiber Optic Particle Plasmon Resonance(FOPPR™) and IN-Chip (auto-flowing microfluidic chip) platform technology for the life science research and in vitro diagnostics markets, enabling molecule measurement of proteins, nucleic acids and cells. The technology of combining FOPPR & IN-Chip can shorten the time consumed in detecting biomarker at the laboratory from three hours to just several minutes and enhance the detection sensitivity (pg/ml) and the detection linear range (5 orders) of devices which allows our product to gather data comparable to top diagnostic laboratories. In the future, miniaturized hand-held devices can be helpful in monitoring prognosis of patients. As data will be sent to the cloud platform, the goal of real-time health management can be achieved.Instant NanoBiosensors already has distributors in 14 states around the world, so we can sell Light Sensing Biomarker Analyzer to laboratories. In the meantime, we hope to build more strategic partnership with international associates. We can assist you in the development and manufacturing of products, meeting demands of laboratory tests in life science. | Seed / Feb 26, 2024 | |
Medi sapiens
|
Medisapiens is a company that pursues the healthy life of patients with rare diseases by integrating bio and artificial intelligence. | Venture - Series Unknown / Feb 26, 2024 | |
Clarius Mobile Health
|
Clarius Mobile Health is focused on the development of a wireless mobile ultrasound ecosystem that enables its users to obtain ultrasound images on their mobile phones.Clarius Mobile Health offers C3 multi-purpose ultrasound scanner operates as both a convex array and virtual phased array probe that enable imaging of abdomens, hearts, and lungs.It organizes events that enable attendees to find information about its products and services.Clarius Mobile Health was founded by Laurent Pelissier and Dave Willis in October 2014. It is based in Burnaby, British Columbia. | Feb 26, 2024 | |
| See all 55 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Artificial intelligence Investors
40,702 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
Health Care VC Funds
32,370 investors
FAQ
What does TMU BioMed Accelerator invest in?
TMU BioMed Accelerator invests primarily in Health Care, Medical Device and Artificial Intelligence startups, most often at Seed and Pre-Seed stage. Most of the 55 investments tracked by Shizune back companies in Taiwan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact TMU BioMed Accelerator?
Public channels for TMU BioMed Accelerator include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at TMU BioMed Accelerator?
The team at TMU BioMed Accelerator includes Jowy Tani (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
